We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-Invasive Neurostimulation For the Relief of Symptoms Associated With Migraine

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01532830
First Posted: February 15, 2012
Last Update Posted: August 6, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
ElectroCore LLC
  Purpose
The purpose of this pilot study is to assess feasibility and clarify the design of future study(ies) to support marketing approval of the GammaCore™ device for the treatment and/or prevention of migraine symptoms.

Condition Intervention
Migraine Device: GammaCore device

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Non-Invasive Neurostimulation of the Vagus Nerve With the GammaCore Device For the Relief of Symptoms Associated With Migraine

Resource links provided by NLM:


Further study details as provided by ElectroCore LLC:

Primary Outcome Measures:
  • Safety [ Time Frame: End of Study ]

Enrollment: 30
Study Start Date: February 2012
Primary Completion Date: July 2012 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Is between the ages of 18 and 55 years.
  • Has been previously diagnosed as suffering from migraine, in accordance with the ICHD-2 Classification criteria (2nd), with or without aura.
  • Experiences at least 2 migraines per month, but less than 15 headache days per month (over the last 3 months).
  • Has age of onset of migraine less than 50 years old.
  • Is able to give written Informed Consent

Exclusion Criteria:

  • Has a history of aneurysm, intracranial hemorrhage, brain tumors or significant head trauma.
  • Has a lesion (including lymphadenopathy) at the GammaCore™ treatment site.
  • Has known or suspected severe atherosclerotic cardiovascular disease, severe carotid artery disease (e.g. bruits or history of TIA or CVA), congestive heart failure (CHF), coronary artery disease or recent myocardial infarction.
  • Has a history or baseline ECG that identifies the presence of a clinically significant unstable cardiac arrhythmia, second degree heart block type II, history of ventricular tachycardia or ventricular fibrillation, or known cardiac syndromes that may be associated with increased risk of sudden death in otherwise healthy people.
  • Has had a previous bilateral or right cervical vagotomy.
  • Has a clinically significant irregular heart rate or rhythm.
  • Has uncontrolled high blood pressure.
  • Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.
  • Has a history of carotid endarterectomy or vascular neck surgery on the right side.
  • Has been implanted with metal cervical spine hardware or has a metallic implant near the GammaCore™ stimulation site.
  • Has a recent or repeated history of syncope.
  • Has a recent or repeated history of seizure.
  • Has a history or suspicion of narcotic abuse.
  • Takes medication for acute headaches more than 10 days per month.
  • Is pregnant, nursing, thinking of becoming pregnant in the next 3 months, or of childbearing years and is unwilling to use an accepted form of birth control.
  • Is participating in any other therapeutic clinical investigation or has participated in a clinical trial in the preceding 30 days.
  • Belongs to a vulnerable population or has any condition such that his or her ability to provide informed consent, comply with follow-up requirements, or provide self-assessments is compromised (e.g., homeless, developmentally disabled, prisoner).
  • Is a relative of or an employee of the investigator or the clinical study site.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01532830


Locations
United States, California
UCSF Headache Center
San Francisco, California, United States, 94143
United States, New York
Montefiore Headache Center
Bronx, New York, United States, 10461
New York Headache Center
New York, New York, United States, 10021
Sponsors and Collaborators
ElectroCore LLC
  More Information

Responsible Party: ElectroCore LLC
ClinicalTrials.gov Identifier: NCT01532830     History of Changes
Other Study ID Numbers: M-US-01
First Submitted: February 10, 2012
First Posted: February 15, 2012
Last Update Posted: August 6, 2014
Last Verified: August 2014

Keywords provided by ElectroCore LLC:
vagus nerve stimulation
vagal nerve stimulation
nVNS
VNS
migraine
non invasive
gammacore

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases